Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Antibody–drug conjugates come of age in oncology
Charles Dumontet, Janice M. Reichert, Peter D. Senter, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 641-661
Closed Access | Times Cited: 346
Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 329
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Payload diversification: a key step in the development of antibody–drug conjugates
Louise Conilh, Lenka Sadílková, Warren Viricel, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 112
Antibody–drug conjugates: Recent advances in payloads
Zhijia Wang, Hanxuan Li, Lantu Gou, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4025-4059
Open Access | Times Cited: 88
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 51
Aptamer-Based Targeted Protein Degradation
Yuan Liu, Xu Qian, Chunyan Ran, et al.
ACS Nano (2023) Vol. 17, Iss. 7, pp. 6150-6164
Open Access | Times Cited: 47
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 30
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Targeting ferroptosis: Paving new roads for drug design and discovery
Yilin Gu, Yizhe Li, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115015-115015
Closed Access | Times Cited: 50
Degrader–Antibody Conjugates: Emerging New Modality
Ki Bum Hong, Hongchan An
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 140-148
Closed Access | Times Cited: 41
A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future
Emily Holz, Martine Darwish, Devin B. Tesar, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 600-600
Open Access | Times Cited: 29
Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins
Qun Zhou
Molecules (2023) Vol. 28, Iss. 3, pp. 917-917
Open Access | Times Cited: 28
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 27
Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
Qi He, Liming Zhou, D.P. Yu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10458-10472
Closed Access | Times Cited: 26
Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Devesh Aggarwal, Jie Yang, Md. Abdus Salam, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 10, pp. 4838-4861
Closed Access | Times Cited: 9
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 8
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads
Meiyang Xi, Jingjing Zhu, Fengxia Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116709-116709
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top